# Quality Considerations for Topical Ophthalmic Drug Products - FDA Guidance Document

Source: https://www.globalkeysolutions.net/guidances/guidance-document/quality-considerations-for-topical-ophthalmic-drug-products/19494a43-f26e-42c9-b1ad-99a1126b3d42

> FDA guidance document: Quality Considerations for Topical Ophthalmic Drug Products. Issue date: December 27, 2023. Get complete insights and analysis.

---

## Details

- Title: Quality Considerations for Topical Ophthalmic Drug Products
- Communication Type: Guidance Document
- Product Type: drugs
- Office Name: Center for Drug Evaluation and Research
- Office URL: /offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c
- Issue Date: 2023-12-27
- Comment Close Date: 2024-02-26
- Last Changed: 2023-12-28
- Docket Number: <a href="https://www.regulations.gov/docket/FDA-2023-D-4177">FDA-2023-D-4177</a>

## Related Documents

- [Establishing Impurity Specifications for Antibiotics](https://www.globalkeysolutions.net/guidances/guidance-document/establishing-impurity-specifications-for-antibiotics/5bb8badb-7c32-4b76-bfc9-bbb8ab55fb84)
- [Clinical Pharmacology Considerations for Peptide Drug Products](https://www.globalkeysolutions.net/guidances/guidance-document/clinical-pharmacology-considerations-for-peptide-drug-products/1609c8ed-4d50-4235-8a00-9c63176affe8)
- [Topical Dermatologic Corticosteroids:  In Vivo Bioequivalence](https://www.globalkeysolutions.net/guidances/guidance-document/topical-dermatologic-corticosteroids-in-vivo-bioequivalence/7cf691b8-82e3-41a4-a550-b4285ce9a9bf)